A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: SHR-7787 injection
Maximum tolerated dose, The Maximum tolerated dose of SHR-7787 injection monotherapy, first dose of study medication up to 21 days|Recommended phase II dose, The Recommended phase II dose of SHR-7787 injection monotherapy, first dose of study medication up to 21 days|Incidence and severity of adverse events (AEs)/serious adverse events (SAEs), Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0, from signature completion of ICF to 60 days after the last dose or to the beginning of the new anti-cancer therapy, whichever came first, assessed up to 24 weeks|Incidence of Dose Limited Toxicity (DLT), Incidence of Dose Limited Toxicity (DLT) described in the protocol, from first dose to 4 weeks
Tmax, PK parameters of single dose of SHR-7787 injection monotherapy, predose, 8 h (hours), 24h, 48h, 72h, 168h post-dose|Cmax, PK parameters of single dose of SHR-7787 injection monotherapy, predose, 8 h (hours), 24h, 48h, 72h, 168h post-dose|AUC0-t, PK parameters of single dose of SHR-7787 injection monotherapy, predose, 8 h (hours), 24h, 48h, 72h, 168h post-dose|t1/2, PK parameters of single dose of SHR-7787 injection monotherapy, predose, 8 h (hours), 24h, 48h, 72h, 168h post-dose|ADA, Anti-drug antibody, Immunogenicity of SHR-7787 in monotherapy, 0.5 hour before first dose through study completion, an average of 1 year|ORR, Objective Response Rate, Efficacy endpoints of SHR-7787 injection monotherapy in treatment of patients with advanced solid tumors, from the date of the first dose to the date of disease progression evaluated based on RECIST v1.1 criteria, death, lost to follow-up, voluntary withdrawal, or initiation of other anti-tumor treatment, whichever occurs first, assessed up to 6 months
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.